Literature DB >> 30824964

Comment on: Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer.

Antoine Girard1, Mathieu Rouanne2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30824964     DOI： 10.1007/s00259-019-04296-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

Review 1.  Partial-volume effect in PET tumor imaging.

Authors:  Marine Soret; Stephen L Bacharach; Irène Buvat
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

Review 2.  Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.

Authors:  Mathieu Rouanne; Mathieu Roumiguié; Nadine Houédé; Alexandra Masson-Lecomte; Pierre Colin; Géraldine Pignot; Stéphane Larré; Evanguelos Xylinas; Morgan Rouprêt; Yann Neuzillet
Journal:  World J Urol       Date:  2018-06-01       Impact factor: 4.226

3.  Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer.

Authors:  Ruohua Chen; Xiang Zhou; Jianjun Liu; Gang Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-09       Impact factor: 9.236

Review 4.  A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.

Authors:  Joaquin Bellmunt; Thomas Powles; Nicholas J Vogelzang
Journal:  Cancer Treat Rev       Date:  2017-02-02       Impact factor: 12.111

5.  Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.

Authors:  Mathieu Rouanne; Reem Betari; Camélia Radulescu; Aïcha Goubar; Nicolas Signolle; Yann Neuzillet; Yves Allory; Aurélien Marabelle; Julien Adam; Thierry Lebret
Journal:  Eur J Cancer       Date:  2019-01-14       Impact factor: 9.162

6.  Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Authors:  Markus Eckstein; Philipp Erben; Maximilian C Kriegmair; Thomas S Worst; Cleo-Aron Weiß; Ralph M Wirtz; Sven Wach; Robert Stoehr; Danijel Sikic; Carol I Geppert; Veronika Weyerer; Simone Bertz; Johannes Breyer; Wolfgang Otto; Bastian Keck; Maximilian Burger; Helge Taubert; Wilko Weichert; Bernd Wullich; Christian Bolenz; Arndt Hartmann; Franziska Erlmeier
Journal:  Eur J Cancer       Date:  2018-12-05       Impact factor: 9.162

7.  Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions.

Authors:  Earle F Burgess; Chad Livasy; Aaron Hartman; Myra M Robinson; James Symanowski; Caroline Naso; Shannon Doherty; Renato Guerrieri; Stephen Riggs; Claud M Grigg; Peter E Clark; Derek Raghavan
Journal:  Urol Oncol       Date:  2019-01-17       Impact factor: 3.498

8.  Integrated analysis of 18F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer.

Authors:  Antoine Girard; Mathieu Rouanne; Sarah Taconet; Camélia Radulescu; Yann Neuzillet; Astrid Girma; Aurélie Beaufrere; Thierry Lebret; Elise Le Stanc; Jean-François Grellier
Journal:  Eur Radiol       Date:  2019-01-21       Impact factor: 5.315

9.  Detecting Metastatic Bladder Cancer Using (18)F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography.

Authors:  Hakan Öztürk
Journal:  Cancer Res Treat       Date:  2015-02-12       Impact factor: 4.679
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.